Drug Information

Drug General Information
Drug ID
D0OR5P
Former ID
DNCL002622
Drug Name
TAS-106
Drug Type
Small molecular drug
Indication Head and neck cancer [ICD9: 140-149, 140-229; ICD10:C07-C14, C32-C33] Phase 2 [522408]
Company
Taiho Pharma U.S.A.
Structure
Download
2D MOL

3D MOL
Formula
C11H13N3O5
Canonical SMILES
C#CC1(C(OC(C1O)N2C=CC(=NC2=O)N)CO)O
InChI
1S/C11H13N3O5/c1-2-11(18)6(5-15)19-9(8(11)16)14-4-3-7(12)13-10(14)17/h1,3-4,6,8-9,15-16,18H,5H2,(H2,12,13,17)/t6-,8+,9+,11-/m1/s1
InChIKey
JFIWEPHGRUDAJN-XAWUEOSKSA-N
PubChem Compound ID
56841052
Target and Pathway
Target(s) RNA polymerase Target Info Modulator
KEGG Pathway Purine metabolism
Pyrimidine metabolism
Metabolic pathways
RNA polymerase
References
Ref 522408ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.